Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Biocartis SA

Biocartis is a commercial stage molecular diagnostics company that develops diagnostics technology platforms for mult... read more Featured Products: More products

Download Mobile App




Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population

By LabMedica International staff writers
Posted on 19 Sep 2025

Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide, and identifying which patients will benefit most from targeted immunotherapies is critical. More...

Existing diagnostic methods can be time-consuming, complex, and limit timely treatment access. Now, a newly approved fully automated diagnostic test enables rapid detection of patients with microsatellite instability-high (MSI-H) colorectal cancer, helping to guide precision therapy choices.

The Idylla CDx MSI Test, developed by Biocartis (Mechelen, Belgium) in collaboration with Bristol Myers Squibb (Princeton, NJ, USA), qualitatively detects a panel of seven MSI biomarkers in colorectal cancer tissue samples. Designed for use on the Idylla Platform, the test requires less than three minutes of hands-on time and delivers results in under three hours through a single-use cartridge system.

The Idylla CDx MSI Test aids in identifying MSI-H colorectal cancer patients who may be eligible for treatment with OPDIVO (nivolumab) alone or in combination with YERVOY (ipilimumab), as established in the CheckMate-8HW clinical trial. Data from this trial reinforced the importance of accurate MSI-H and dMMR testing in guiding immunotherapy use.

The Idylla CDx MSI Test has received FDA Premarket Approval as the first cartridge-based, fully automated sample-to-result companion diagnostic for colorectal cancer. The FDA approval of the assay underscores its validation as a reliable companion diagnostic for precision oncology applications. This breakthrough allows oncologists to match patients more quickly with life-extending therapies, eliminating delays caused by conventional lab processes.

With FDA approval secured, the Idylla CDx MSI Test will soon be available across the US, with international availability expected to follow. By expanding access to automated, accurate MSI testing, the platform has the potential to improve global standards of cancer care and strengthen precision medicine strategies.

“Rapid and accurate diagnosis is crucial to enabling access to appropriate therapeutic approaches, and this latest advancement exemplifies our commitment to delivering innovative, targeted solutions that have the potential to improve outcomes for patients,” said Sarah Hersey, Vice President, Precision Medicine, Bioanalytical and Translational Sciences, Bristol Myers Squibb.

“Achieving FDA approval for our Idylla CDx MSI Test represents a key milestone for Biocartis,” said Michael Korn, M.D., Chief Medical and Scientific Officer at Biocartis. “It underscores our commitment to helping oncology patients receive the right therapy without delay and the recent CheckMate-8HW data reinforce the critical importance of accurate MSI-H/dMMR testing in colorectal cancer. With its speed, accuracy, and automation, the Idylla CDx MSI Test offers a powerful solution that enables clinicians to make timely, confident, and data-driven treatment decisions when every moment counts.”

Related Links:
Biocartis
Bristol Myers Squibb


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.